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Abstract
Background: Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of
refractory recurrent clostridial colitis (rCDI). Success of FTM in treatment of rCDI led to a number of studies investigating
the effectiveness of its application in the other gastrointestinal diseases. However, in the majority of studies the effects
of FMT were evaluated on the patients with initially altered microbiota. The aim of our study was to estimate effects of
FMT on the gut microbiota composition in healthy volunteers and to monitor its long-term outcomes.
Results: We have performed a combined analysis of three healthy volunteers before and after capsule FMT by
evaluating their general condition, adverse clinical effects, changes of basic laboratory parameters, and several
immune markers. Intestinal microbiota samples were evaluated by 16S rRNA gene and shotgun sequencing. The data
analysis demonstrated profound shift towards the donor microbiota taxonomic composition in all volunteers.
Following FMT, all the volunteers exhibited gut colonization with donor gut bacteria and persistence of this effect for
almost ∼1 year of observation. Transient changes of immune parameters were consistent with suppression of T-cell
cytotoxicity. FMT was well tolerated with mild gastrointestinal adverse events, however, one volunteer developed a
systemic inflammatory response syndrome.
Conclusions: The FMT leads to significant long-term changes of the gut microbiota in healthy volunteers with the
shift towards donor microbiota composition and represents a relatively safe procedure to the recipients without
long-term adverse events.
Keywords: Fecal microbiota transplantation, Healthy volunteers, Metagenomics, 16S rRNA gene sequencing,
Shotgun sequencing, Metagenome-assembled genome, Compositional data analysis
Background
Human gut microbiota is a key player in human body
metabolism. Gut microbiota begins to develop from birth
and its composition depends on multiple factors: deliv-
ery type, nosocomial microflora at the obstetrics unit,
maternal diet, breastfeeding etc. [1, 2]. The microbiota is
extremely important for the maintenance of physiological
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homeostasis including synthesis of vitamins and essen-
tial amino acids, short-chain fatty acids (SCFA), e.g.,
butyrate, propionate, acetate which serve as energy sub-
strates for epithelial cells as well as inactivation of toxic
substances [3]. Antibacterial and/or cytostatic treatments
trigger profound changes in gut microbiota composition
reducing bacterial diversity and increasing predominance
of pathogenic microorganisms that facilitate damage to
a gut epithelium barrier and/or alter immune system
response [4].
Fecal microbiota transplantation (FMT) from allo-
geneic donors has become a popular approach to the
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microbiota correction. Recently, the FMT procedure was
approved by the FDA (Food and Drug Administra-
tion) for application in the setting of clinical trials in
recurrent clostridial colitis (recurrent Clostridium diffi-
cile infection – rCDI) [5]. However, several procedure
limitations still exist, thus precluding wider implemen-
tation of this technology, especially in other clinical
settings [6].
Growing interest to this method is determined by
a high response rate (>90%) in rCDI, including cases
with multiple antibiotic resistance [7], positive thera-
peutic effect in severe cases of ulcerative colitis [8],
Crohn’s disease [9], as well as by a relatively simple
application method. There is also evidence of FMT
efficacy in correcting microbiota following antibacterial
treatment [10]. A number of published data provide
evidence for the effectiveness of FMT in complex ther-
apy of autoimmune diseases [11], antibiotic-associated
diarrhea, and in graft-versus-host disease occurring
after hematopoietic stem cell transplantation [12, 13].
The FMT procedure results in reduced prevalence
of gut Enterobacteriaceae with multiple resistance to
beta-lactam antibiotics and carbapenems, vancomycin-
resistant Enterococcus spp. (VRE), methicillin-resistant
Staphylococcus aureus (MRSA) [14], Klebsiella pneumo-
niae and other drug-resistant bacteria [15–17]. These
observations are particularly valuable in the light
of the high mortality caused by antibiotic-resistant
pathogens [18].
It has been previously shown that FMT induces multi-
ple changes in the gut microbiota composition [19, 20].
The main mechanism of FMT effects in inflammatory
bowel diseases (IBD) is believed to be associated with col-
onization of the gut with donor microbiota [21]. However,
there is a lack of data on the exact mechanisms behind
FMT efficacy. Kump et al., have shown that the changes
in taxonomic spectrum of a donor microbiota is the main
factor determining FMT efficacy in patients with ulcer-
ative colitis [22]. On the other hand, colonization with
donor microbiota may, of course, promote the metabolic
potential of the recipient microflora, thus causing clini-
cal improvement. However, these studies were carried out
by treating already severely ill patients, or in vivo animal
models. Despite encouraging results with FMT in differ-
ent clinical settings, we have not found any data on typical
effects of FMT in healthy subjects, evaluating and/or
tracing the microbiota shifts, and investigating the appro-
priate immune system responses. These data would allow
better understanding of the changes after the treatment
in different clinical disorders and may specify changing
patterns of the host-donor microbiota interrelations after
FMT.
Despite the convincing success of FMT, a number of
adverse effects ranging from abdominal complaints to
fever, bacteremia, and exacerbation of underlying diseases
were reported [23]. However, the data addressing possible
FMT complications in healthy volunteers treated by allo-
geneic microbiota are still lacking. A knowledge of FMT
effects in healthy and diseased persons will enable bet-
ter awareness of participants at future FMT clinical trials
seeking for safety and health risk minimization among
the study subjects. Hence, the aim of our study was to
evaluate effects of FMT upon gut microbiota in healthy
persons following FMT from a healthy donor, as well as
basic parameters of the immune system before and after
this procedure.
Methods
Donor and volunteers selection
A woman, in her mid-thirties, was chosen as a donor
(body mass = 54 kg, BMI = 19.4). She received a usual,
balanced, European diet over the entire period of the
study and was clinically evaluated according to a protocol
recommended by the European Consensus Conference
on Faecal Microbiota Transplantation in Clinical Practice
[24]. Firstly, the donor has been good health, being sub-
jected to an annual routine medical checkup. Her physical
condition, blood counts and routine serum biochemistry
were found to be within normal limits for the preced-
ing 3 years. No dyspepsia or other stool abnormalities
were reported within last year. Routine clinical and lab-
oratory examinations such as clinical blood cell counts,
biochemical blood analysis, and evaluation of lympho-
cyte subpopulations showed no abnormalities, as well
as human viruses blood testing (such as HIV, hepatitis
A-E, CMV, Epstein–Barr virus, HSV-1, HSV-2, HHV-6)
were negative. Syphilis blood testing was also negative.
Secondly, donor stool has been thoroughly examined:
(1) PCR for intestinal microorganisms including oppor-
tunistic species (Colonoflor-16, LLC Alfa Lab, Russia);
(2) bacteriology for antibiotic resistance such as MRSA,
VRE, ESBL, carbapenemase-producing Klebsiella pneu-
moniae and Escherichia coli; (3) study of fecal calpro-
tectin; (4) examination for Clostridium difficile toxins
A and B; (5) PCR testing for enteropathogenic viruses:
CMV, Epstein-Barr virus, HSV-1, HSV-2, HHV-6, human
adenoviruses (types B, C, E), noroviruses (types 1, 2),
rotaviruses (types A, B, C), enterovirus; (6) parasites test-
ing including protozoa and helminths. After 90 days,
the repeated blood tests were performed as described
above. Implemented clinical testing didn’t show abnor-
malities. Three consequent donor samples were collected:
baseline specimens (used for FMT), as well as 193 and
385 days later.
Full awareness of the volunteers of the study purpose,
perform and possible adverse effects from treatment, were
strictly followed through, as stated by approved informed
consent signed by each participant in this study. The
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volunteers’ medical information was anonymized. Access
to full information was available only to the doctor.
Volunteers were physically and mentally healthy. They
kept a standard European diet. After the procedure
participants were monitored in the outpatient depart-
ment of R.M. Gorbacheva memorial institute and had
access to all services such as bone marrow transplant
recipients, including daily care, 24/7 on-call haematolo-
gist and opportunity for hospitalization. The summary
data on the volunteers and the donor are presented in
Additional file 6: Table S1.
Treatment schedule
We have used the FMT protocol including dosage and
timing of the procedure, as well as observation terms
which, in general, correspond to the protocol from the
clinical trial NCT03214289. The workflow of the study
was used in other clinical trials applied for the treatment
of different gastrointestinal disorders [25]. The FMT pro-
cedure was performed in three healthy volunteers (38.6
±7.4 years old, two male and one female). Volunteers
were assigned IDs – V1, V2 and V3. The treatment was
two-staged: the first stage consisted of the administration
of 15 capsules containing donor stool on one day, and
15 capsules on the next day. Mild breakfast was allowed
4 hours before administration. One hour before treat-
ment, each volunteer took a dose of omeprazole (20 mg).
The volunteers were administered solid gelatin capsules
(Coni-Snap size 4) containing frozen at -20 °C feces, fol-
lowed by drinking water. The anticipated weight of the
material for every single volunteer was 22 g in 30 cap-
sules. The clinical follow-up continued for 300-303 days.
In total, 22 fecal and blood samples of volunteers were
collected. The gut metagenomic study was performed for
the first volunteer in ten time points; he underwent two
FMTs (the second FMT was carried out 38 days after
the first FMT). The second volunteer (V2) was adminis-
tered half of the anticipated dose due to the development
of systemic inflammatory response syndrome (SIRS). The
third volunteer was administered the full anticipated dose.
Adverse effects (AE) were assessed using the Toxicity
Scale (Common Terminology Criteria for Adverse Events
(CTCAE) Version 5.0 Published: November 27, 2017).
The same protocol of fecal microbiota transplantation was
approval and used for patients with refractoryClostridium
difficile infection and graft-versus-host disease in Pavlov
First Saint Petersburg State Medical University hospital
practice [26]. The study description scheme presented in
Fig. 1.
Sample collection, preparation and sequencing
Collection of stool samples was performed in sterile
plastic containers, both before FMT and at different time
points later on. DNA was extracted using PureLinkTM
Microbiome DNA Purification Kit (InvitrogenTM, USA)
according to the manufacturer’s protocol. 16S library
preparation and sequencing were done according to
Illumina protocol (16S Metagenomic Sequencing Library
Preparation). Briefly, extracted DNA was amplified using
standard 16S rRNA gene primers, complementary to
V3-V4 region and containing 5’-illumina adapter
sequences. In the next step individual amplicons
were PCR – indexed and pooled. DNA libraries were
sequenced on a MiSeq instrument (Illumina, San Diego,
CA, USA) using Miseq reagent kit v3 (Illumina, San
Diego, CA, USA). For shotgun sequencing, 300 ng of
DNA were sheared by sonication with the Covaris S220
System (Covaris, Woburn, Massachusetts, USA). The
final sizes of fragmented DNA samples were determined
on Agilent 2100 Bioanalyzer (Agilent, USA) using the
manufacturer guide, and were approximately 400-500 bp
long. Paired-end libraries were prepared according to the
manufacturer’s recommendations using NEBNext Ultra
II DNA Library Prep Kit (New England Biolabs, USA).
The libraries were indexed with NEBNext Multiplex
Oligos kit for Illumina (96 Index Primers, New England
Biolabs, USA). Size distribution for the libraries and
their quality were assessed using a high-sensitivity DNA
chip (Agilent Technologies). The libraries were subse-
quently quantified by Quant-iT DNA Assay Kit, High
Sensitivity (Thermo Scientific, USA). DNA sequencing
was performed on the HiSeq 2500 platform (Illumina,
USA) according to the manufacturer’s recommenda-
tions, using the following reagent kits: HiSeq Rapid PE
Cluster Kit v2, HiSeq Rapid SBS Kit v2 (500 cycles),
HiSeq Rapid PE FlowCell v2 and a 2% PhiX spike-in
control.
Dynamic monitoring of clinical blood cell counts,
biochemical blood analysis, and evaluation of lympho-
cyte subpopulations was performed in the recipients.
Immunophenotyping was performed with a flow
cytometer Cytomics FC500 (Beckman Coulter, USA)
with CXP Analysis software (Beckman Coulter) using
fluorochrome-labeled monoclonal antibodies (CD45
FITC/CD4 PE/CD8 ECD/CD3 PC5, CD19PC7, CD3
FITC/CD(16+56) PE, CD45 PC5, CD5 FITC/CD23
PE/CD19 ECD, CD27PC7, purchased from Beckman
Coulter, USA) and Versalyse wash-free lysis (Beckman
Coulter, USA).
Statistical and bioinformatic analysis
The results of 16S rRNA gene sequencing were indepen-
dently evaluated by two different computer tools. First
tool: metagenomics 16S rRNAWorkflow MiSeq Reporter
Package, provided together with Illumina sequencing plat-
form with applied the GreenGenes database [27]. Second
tool: DADA2 pipeline [28] and 16S SILVA database [29]
was applied to predict the taxonomic annotation using
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Fig. 1 Study description. The first line describes sampling points, the second line clinical effect observable caused by taking FMT capsule. The third
line describes obtaining sequencing data and bioinformatic analysis. The sampling and sequencing points are presented in Additional file 6: Table S1
QIIME2 [30]. Due to the compositional type of such
data (CoDa) to WGS data analysis evaluation required
CoDa analysis approaches [31] such as Aitchison distance
[32, 33] with the aid DEICODE [34]. The sequence
quality filtration for the WGS metagenomic data was
performed by means of the "metaWRAP read_qc" mod-
ule [35]. To obtain taxonomic compositions for metage-
nomic WGS data, we used MetaPhlAn2 [36, 37]. CoDa
approaches (Aitchison distance) and non-metric multidi-
mensional scaling (NMDS) were used for bi-dimensional
visualization. A balance dendrogram (CoDa dendrogram)
was used for building a model of ecological succession of
recipient gut microbiota due to FMT. This dendrogram-
like graph shows: (a) the way of grouping parts of the
compositional vector; (b) the explanatory role of each sub-
composition generated in the partition process; (c) the
decomposition of the total variance into balance com-
ponents associated with each binary partition [38, 39].
Before the analysis, removal of rare taxa and substitution
of zeros by Bayesian estimation of (non-zero) proportions
were performed [40]. For additional analysis unweighted
UniFrac distance and Bray-Curtis dissimilarity was used.
Visualization was performed in the R statistical envi-
ronment using vegan package [41] and ggplot2 library
(https://ggplot2.tidyverse.org).
To trace distinct donor-derived strains in the recip-
ient metagenomic data we used genome-resolved
metagenomic (GRM) approaches based on metagenome-
assembled genomes (MAGs). To assemble the MAGs,
individual samples from donor and each recipient were
used separately. The metaWRAP pipeline was used for
the MAGs assembly [35] (contain MEGAHIT [19], CON-
COCT [42], MetaBAT2 [43], MaxBin2 [44], and BWA
[45]), with the following parameters of resulting bins:
completeness >70%, contamination <10%, nucleotide
length >2,000,000 bp. Multiple alignments for 43 marker
MAGs segments (amino acid sequences), plotting a
phylogenetic tree, and subsequent taxonomic annotation
was performed by means of CheckM [46].
The MAGs were clustered by alignments, guided by
100% amino acid (AA) similarity between the studied
sequences (dist.alignment from seqinr package for R [47]).
The clusters obtained were then additionally compared
(using full MAGs sequences) by their nucleotide simi-
larity using OrthoANI [48]. To follow the dynamics for
donor MAGs in metagenomic samples from recipients,
the Anvi’o framework [49] (including Prodigal tool [50]),
and Bowtie2 [45] was applied, suggesting a design of
contig database from the donor-derived MAGs, align-
ment of metagenomic samples, as well as visualization
Goloshchapov et al. BMCMicrobiology          (2019) 19:312 Page 5 of 13
of the resulting data. Additionally, for tracking donor-
derived bacteria in recipient metagenomes metaSNV [51]
profiling based on mOTUs2 pipeline database [52] was




Clinical observations of the volunteers were performed
during the first month post-FMT. The AEs were reg-
istered for all the subjects 8 to 10 hours after taking
the capsules (Additional file 6: Table S2). There was no
emerging AE past the first 24 hours. V1 and V3 exhib-
ited only grade 1 gastrointestinal AEs post-FMT. The
second volunteer (V2) developed a SIRS. Dynamic mon-
itoring of clinical blood cell counts, biochemical blood
analysis, and evaluation of lymphocyte subpopulations
are presented in Fig. 2. On day 2 of treatment, all
laboratory tests were in the normal range, except for
increased blood neutrophil counts from 59.1% (5.1×109/l)
to 70.6% (8.9×109/l), and from 61.4% (6.3×109/l) to 70.7%
(6.9×109/l), for V1 and V2, respectively. Blood lympho-
cyte counts showed a decrease from 31.7% to 23.6%,
at similar absolute lymphocyte numbers (2.8×109/l and
3.0×109/l). V3 exhibited a relative decrease of lymphocyte
counts, both in percentage (30.1% to 17.8%) and in abso-
lute values (2.8×109/l to 1.7×109/l). A limited number of
immune parameters included counts of total leukocytes
and their main subpopulations. Gross changes in total
leukocyte and neutrophil counts were observed in V1 and
V2. Meanwhile, the CD3+/CD4+ and CD4+/CD8+ ratios
seemed to increase by day +8 after FMT, with a rapid
reversal to normal values. These changes do not mean
any prolonged immune depression, as compared, e.g., to
leukopenia observed following cytostatic therapy. Rather,
they resemble a systemic acute response to antigenic
stimulation.
For V2, we observed a number of pronounced symp-
toms, which required additional therapy. Ciprofloxacin
was administered at a daily dose of 500 mg for 3 days,
and the 2nd round of FMT in this subject was can-
celed. V2 developed a clinical pattern of the systemic
inflammatory response (fever, with the one-time rise of
body temperature to 39.1 °C, with shivers and tachy-
cardia of 102 per minute on the day after administra-
tion). The blood changes corresponded to acute bacterial
infection: leukocytosis to 16.7×109/l, neutrophils 90.6%
(15.1×109/l), absolute lymphopenia (0.9%, 0.2×109/l).
Blood smear counts showed an increase in band forms,
10% (1.67×109/l), segmented forms, 80% (13.36×109/l);
toxic granulation in neutrophils and decrease of lym-
phocytes, 4% (0.66×109/l). C-reactive protein levels were
within normal ranges, a marginal increase of γ -glutamyl
transpeptidase to 56.7 U/l (normal range: 0-55 U/l) and
ALT to 62 U/l (normal range: 0-50 U/l) was noted
on day +2. Clinical chemistry parameters of V1 and
V3 were within normal ranges during the treatment
course.
The lymphocyte subpopulations were examined before
FMT, as well as on day +9 and day +30. By day +9,
an increased percentage and absolute numbers were
observed for T-helpers CD3+CD4+, CD19+CD23+
cells; CD4/CD8 ratio; as well as a decrease in lym-
phocyte subpopulations, i.e., T-cytotoxic CD3+CD8+
lymphocytes, and NK cells (CD3-CD16+56+). By
day 30, a reverse dynamics to normal values was
revealed. The number of recipients was insufficient
to evaluate the statistical significance of the observed
changes. However, we could be assumed an associ-
ation between adverse effects and immune system
perturbation.
Gut microbiome changes after FMT
16S rRNA gene sequencing (16S seq) data analysis was
performed in two independent laboratories and the
results were consistent in both assays. Summary sequenc-
ing statistics are presented in Additional file 6: Table S3.
The NMDS bi-dimensional plot obtained with using
Aitchison distance and 16S seq taxonomic data is pre-
sented in Fig. 3. It shows the convergence of the recipients’
gut taxonomic profiles to the donor profile within 300
days after the FMT. Interestingly, the gut metagenomic
profile of V1 showed a dramatic change after the sec-
ond FMT round procedure from the same donor (2 days
after the second FMT round). However, further sam-
ples showed a return to the donor pattern. Additionally,
analysis using NMDS and unweighted UniFrac dis-
tance confirmed previous results (see Additional file 1:
Figure S1A).
Shotgun metagenomic sequencing was another method
for studying changes in the intestinal microbiota profile
of the recipients, which yielded 23.1 ± 3.7 M of 250 bp
reads per sample (98.3 Gbp in total) after quality control.
Seventeenmetagenomic samples were sequenced with the
shotgun method (6 for the V1, 4 for the V2 and V3 and 3
samples for the donor). The sequencing summary statis-
tic is presented in Additional file 6: Table S3. A total of 74
genera were detected in all samples. The dataset of relative
abundances of bacterial genera is shown in Additional
file 6: Table S4. The shotgun sequencing confirmed
the 16S seq data with a similar pattern of changes
towards the donor profile (Fig. 4a). Similar results
were obtained by NMDS bi-dimensional visualization
using Bray-Curtis dissimilarity (see Additional file 1:
Figure S1B).
For constructing the model of microbiota succession
caused by FMT, the balance dendrogram (CoDa den-
drogram) was used. This approach allows identifying
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Fig. 2 Dynamics of neutrophil counts, lymphocyte counts (a) and lymphocyte sub-populations after FMT (b). The second volunteer (V2) developed
SIRS
specific balances (ratio between taxonomic abundances)
that are involved in the reshaping of the microbiome of
recipients [31, 38]. This model describes the intensity
of taxonomic reshapes when moving the recipients’
profiles to the donor-specific parameters (see Fig. 4b).
Immediately, on the fifth day after FMT, the recipients
relatively increased the content of Prevotellaceae,
unknown Burkholderiales, Erysipelotrichaceae, Vel-
lonellaceae, and Desulfovibrionaceae; however, the
shift towards Prevotellaceae, unknown Burkholderiales,
was more pronounced at day 5. At the same time,
the relative increase of Lachnospiraceae, Oscil-
lospiraceae, Rumminococaceae, Sphingomonadaceae,
Bradyrhizobiaceae, Bifidobacteriaceae and Coriobac-
teriaceae occurred less quickly and more smoothly.
Also, the relative abundance of Enterobacteriaceae,
Bacteroidaceae, Porphyromonadaceae, Rikenellaceae,
unknown Bacteroidales, Eubacteriaceae, and Strepto-
coccaceae decreased gradually towards the donor-like
profile.
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Fig. 3Movement of recipient samples to the donor during the observation time based on 16S rRNA gene sequencing taxonomic composition.
Bi-dimensional plot obtained by Aitchison distance with the aid of DEICODE. Donor samples: X. Volunteer’s samples: red / blue / green colors (see
figure legend). The lines denote the evolution of the volunteer’s samples in time (different time points). The days after FMT procedure (or baseline
for donor samples) denoted by color numbers
Fig. 4 Shifts of the taxonomic profile of microbiota in volunteers towards donor values over the observation time. The figure is based on shotgun
sequencing data. a on-metric multidimensional scaling bi-dimensional plot of MetaPhlAn2 taxonomic profile (genera level relative abundances),
based on the Aitchison distance. The lines denote the evolution of the volunteer’s samples in time (different time points). The days after FMT
procedure (or baseline for donor samples) denoted by numbers. b CoDa dendrogram which characterizes association of bacterial families, balances
presented as edges. Decomposition of total variance by balances between groups of families is shown by vertical bars. Mean values of balances is
shown by anchoring points of vertical bars. Color of vertical bars corresponds to time points. Color rectangles highlighted families belonging to
important balances. The arrows direction indicates the predominance of this balance part in the donor. MOTUs with no family information are
collapsed into the no-name family
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Altogether, the obtained results show a directed change
in the gut microbiota composition of volunteers, namely
pre-FMT profiles of the recipient microbiota have
changed after FMT and become similar to the donor
microbiota.
Identification of donor bacteria in the recipient
metagenomes
Taxonomic profiling methods may reveal general changes
of the taxonomic profile for the gut microbiota.
However, it is important to examine the engraftment of
the donor bacteria in recipients. To assess the engraftment
of the donor bacteria using the obtained shotgun sequenc-
ing data, we used genome-resolved metagenomics –
an approach allowing to restore bacterial genome from
the metagenomic data (metagenome-assembled genomes
– MAGs). This method is based on the metagenomic
assembly and clustering of contigs through a metage-
nomic binning procedure and others specific manipula-
tions (see “Methods” section). As a result, 243MAGs were
assembled for all metagenomic samples both from donor
and recipients. For the donor 46 MAGs were obtained,
for each of the volunteers 87, 56, and 54 MAGs, respec-
tively (note that these MAGs represent microbes from
both pre- and post-FMT time points). Further, based on
43 marker single-copy proteins, the place at the dendro-
gram for eachMAGwas determined (see Additional file 2:
Figure S2), and appropriate taxonomic annotation was
ascribed with the CheckM tool. We detected 14 donor-
like MAGs in which 100% amino acid similarity of marker
proteins was observed (see Fig. 5a). The changes in the
relative abundance of these 14 MAGs are shown in Addi-
tional file 3: Figure S3. The similarity of the nucleotide
sequence (average nucleotide identity – ANI) between
donor and recipient MAGs was also high (see Fig. 5b).
Anvi’o visualization for the mapping results of the reads
from recipient samples in the donor MAGs is shown
in Fig. 5c.
DONOR_BIN_26 didn’t show the 100% amino acid
homology with MAG of V1 and V3. However, they were
similar in their nucleotide composition. These discor-
dances could be explained by some metagenomic assem-
bly artefacts and binning, thus resulting in chimeric con-
tigs. The given approach shows a rather big number of
false-negative results; however, it allows to detect suc-
cessful cases from nonspecific findings. Of 14 donor
MAGs with complete amino acid sequence similarity in
marker proteins, 10 may be considered as successfully
engrafted in at least one recipient. The DONOR_BIN_28,
DONOR_BIN_47, DONOR_BIN_22, DONOR_BIN_22,
DONOR_BIN_22 did not enter this list due to the fol-
lowing reasons: (1) nucleotide identity from recipient
MAGs (threshold <99.90% ANI); (2) they were covered
by reads after FMT (not 100% certainty of their donor
Fig. 5 Comparison of similarity between donor and recipients metagenome-assembled genomes (MAGs). a The AA distance based on 43 marker
proteins between all donor MAGs and all MAGs of all recipients. Arrow shows that some MAGs in donor and recipient is present with absolute
similarity of marker genes sequence. b The average nucleotide identity (ANI) between similar donor and recipients MAGs. The MAGs with 100% AA
similarity of 43 marker proteins were selected. c Anvi’o plot denoted prevalence of donor MAGs across all metagenomic samples. Detection value
(proportion of nucleotides in a contig that are covered at least 1x (according to http://merenlab.org/2017/05/08/anvio-views) was used as an
abundance metric, which is shown as color brightness. Black color denotes detection value of donor MAGs in the donor samples, red – in the V1
samples, blue – in the V2 samples, green – in the V3 samples. DONOR BIN – clusters of metagenome-assembled genomes similar to the donor
bacteria. The days after FMT denoted by numbers. The mapping of recipient metagenomic reads to donor MAGs was performed with 100% similarity
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origin). By taxonomic annotation, these "strong" coloniz-
ers belong to the following orders: Bacteroidales (n=5),
Clostridiales (n=3), Selenomonadales (n=1). Many donor
MAGs didn’t show 100% similarity with recipients MAGs
in the two parameters described above. However, this
MAGs appeared in the recipients after FMT. This can
be explained by the chimeric contigs and/or sequencing
errors when assembling recipients MAGs. In addition,
similar recipient bacteria can increase after FMT.
Ten MAG clusters, similar in amino acid sequences of
marker proteins, were exclusively present in the recipi-
ent metagenomes (see Additional file 3: Figure S3). Based
on the criteria of an nucleotide similarity (ANI >99.90%),
there is evidence that the observed changes of several
genera of bacteria abundances were donor-independent.
Either these expanding bacteria were in donor samples,
but were not found due to insufficient read coverage,
or the FMT procedure induces the relative expansion of
certain types of recipient bacteria (for example, see Addi-
tional file 3: Figure S3A). We have also revealed 4 cases
of similar MAG sets in V2 and V3 that decreased rel-
atively after FMT in both recipients. V2 and V3 have
similar patterns of decrease and increase of some similar
MAGs (see Additional file 3: Figures S3 D, F, H, I, J and
Additional file 4: Figure S4). More detailed information
about MAGs assembly is presented in Additional file 6:
Table S5.
Additionally, SNV-profiling using mOTUs2 pipeline
and metaSNV was performed. We detected that after
FMT the number of mOTUs identical to donor were
increased. The results are present in Additional file 5:
Figure S5.
Discussion
FMT has been increasingly used for the treatment of dif-
ferent disorders. The majority of studies have focused
on the evaluation of FMT consequences in patients with
rCDI, ulcerative colitis, and Crohn’s disease. It was specu-
lated that in these diseases the therapeutic effect is based
on the expansion of the donor flora and on the correction
of defects in the species composition [53–55]. The cor-
rection of the intestinal microbiome leads to the restora-
tion of short-chain fatty acids and bile acid metabolism,
altered immune response, the profile of cytokines and
chemokines, and augmentation of intestinal wall repara-
tion. The mentioned processes may be immediately or
indirectly affected by other medications, e.g. granulo-
cytic colony-forming factor, glucocorticosteroids used in
hematopoietic stem cell transplantation, antibiotics used
in pseudomembranous colitis, aminosalicylates, anti-TNF
monoclonal antibodies in Crohn’s disease, and nonspe-
cific ulcerative colitis. While the changes in microbiome
after FMT are well established, it is unclear whether
they can be attributed only to FTM, as more complex
mechanisms may be involved. Therefore, the study of
FMT effects in healthy volunteers is important to under-
stand the mechanisms behind the efficacy of this proce-
dure and potentially to improve its outcome for patients
(e.g. by rules of donor selection).
The present study resulted in several important
findings. First, we demonstrated that FMT even with
a small stool mass (11-22 g) induces profound changes
in healthy persons with normal microbiota composition.
The convergence of the recipient taxonomic composition
to the donor-like state following the FMT procedure was
demonstrated for various diseases [55–58], but compa-
rable changes were observed in the healthy volunteers.
Thus, the effects of FMT are comparable in the normal
and pathological conditions, indicating that the replace-
ment of the missing bacterial populations is not a unique
event for disease conditions. Second, we observed that
the composition of the gut flora is altered due to engraft-
ment of donor bacteria. Although a sequencing artefact
cannot be excluded, all published studies with FMT indi-
cate significant increase in the overall bacterial diversity,
which is not only related to the growth of the donor flora
[59, 60]. The potential mechanisms behind the activation
of recipient flora might be horizontal gene transfer [61],
effects of the non-bacterial stool components [62], and
functional interactions between microbial communities
[63]. Further studies are required to elucidate the exact
mechanism(s). However, we have identified some features
of the restructuring process. Prevotellaceae and unknown
Burkholderiales colonize faster than others. This might
be a "hub" bacteria that allow to develop a new "ver-
sion" of the recipient gut community, which would include
recipient-derived and donor-derived characteristics.
The number of potential applications of FMT is
exponentially growing: decolonization from antibiotic-
resistant bacteria prior to stem cell transplantation [60],
modulation of response to cancer immunotherapies, like
anti-PD-1 antibodies [64], vaccination against respira-
tory pathogens [62], amelioration or prevention of non-
gastrointestinal infections, like malaria [65], treatment of
autism [43] and depression [66]. However, there is no evi-
dence that FMT induces long term changes in subjects
with no previous damage to microbiota due to antibiotics
treatment or to the underlying condition. This study pro-
vides the first proof of principle that, even in a healthy
person, the procedure induces long-term changes with
a shift towards donor profile. Here we show that FTM
induced several gastrointestinal adverse events and early
inflammatory response at day 2 in V1 and V2 cases, i.e., a
shift to band leukocyte forms with normal C-reactive pro-
tein levels in healthy recipients. This suggests the devel-
opment of massive antigenic exposure with leukocytosis
where, even in the absence of detectable evidence, the
development of septic state requiring antibiotic treatment
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cannot be excluded. Indeed, a SIRS-like syndrome was
diagnosed in one of our cases (V2), thus requiring urgent
antibiotic therapy. It should be regarded as a serious
adverse effect of FMT occurring in an obviously healthy
immunocompetent person [23]. The adverse effects after
FMT are classified as mild, serious and severe. Lethal
outcomes following FMT are accidental and are most
likely associated with underlying disease, or exacerbating
comorbidities. A recent detailed review of the side effects
in FMT was based on data obtained from 1998 to 2015
[67]. Severe AEs were mostly related to endoscopic pro-
cedures and aspiration. The use of capsule FMT seems to
minimize the risk of the procedure. The observed mild
adverse effects may require correction using only symp-
tomatic therapy, like anti-inflammatory and spasmolytic
drugs. Leukocytosis and neutrophilia, along with relative
and absolute lymphopenia may be a near-normal vari-
ant following FMT. One volunteer did receive a short
treatment of ciprofloxacin for systemic inflammatory
response syndrome (SIRS), but the sequencing data still
indicated the shift towards the donor pattern of the
microbiota. In the previous study, though, early antibi-
otic use was reported to compromise the efficacy of the
procedure [68].
Although the study group was small, the observed
changes were consistent with previous preclinical stud-
ies [69, 70] and case reports [71]. There was a transient
decrease in total lymphocyte count, a decrease of CD8+
cells, decrease of NK cells and increased CD4/CD8 ratio.
The effect wasmost prominent in the volunteer with SIRS.
The downregulation of lymphocyte response might have
comparable mechanisms to the one induced under bac-
terial septic conditions [72]. This AE might be one of
the mechanisms behind the FMT benefit in autoimmune
disorders.
In the clinical studies it was demonstrated that the
efficacy of FMT was based on such genera as Ruminococ-
caceae, Lachnospiraceae and Prevotellaceae [59, 73].
These were the bacterial species that were consistently
expanded in the volunteer samples. It is unclear if they
directly drive the therapeutic effect of the FMT or are just
a marker of the changes that induce the response. The
question regarding the optimal donor and driving force
for each indication is still open. Only accumulation of
clinical observations will give the answer to this intrigu-
ing question. Another approach used by the industry in
the early clinical trials is the mixture of products from
a large number of donors (https://clinicaltrials.gov/ct2/
show/NCT03497806), but the benefits and drawbacks of
such an approach are still to be evaluated.
Our study, though rather limited, shows some poten-
tial risks of the allogeneic FMT procedure, even when
performed in healthy volunteers. Appropriate studies in
healthy persons should be performed cautiously under
strict medical supervision. The FMT procedure should be
administered only if the expected benefits sufficiently pre-
vail over the possible risks. Moreover, the FMT protocol
should be detailed and reproducible to obtain stable
clinical outcomes.
Conclusions
The main conclusion of the present study is the con-
firmation of the long-term microbiota composition con-
version by FMT in healthy subjects. The microbiome
composition in recipients shifted towards the donor
profile. The most important finding was the rela-
tive expansion of donor-derived bacteria inside healthy
recipients gut. Additional important findings may be
certain rules of community succession after FMT.
Perhaps in the future, the description of these rules will
allow the microbiota to be controlled and directed from
one state to another. However, researchers and physicians
should take a responsible approach to the FMT procedure
and apply this procedure only when the positive effects far
exceed the possible risks, since fecal transplantation may
be associated with severe side effects.
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